A Study of IGN002 for Refractory NHL

Summary

This is a Phase 1 multi-center, open-label study that allows subjects who derived clinical benefit after completing IGN002 treatment in the Spectrum sponsored IGN002-101 study to continue treatment with IGN002. Subjects who completed the IGN002-101 study, tolerated IGN002 treatment, and did not experience progressive disease (PD) are eligible to participate in this study.

Timeline

Start

2021-01

Primary completion

2025-07

Completion

2025-12

Outcome

Outcome not reported

Stopped (Business): “Strategic Reasons”

Drugs

Indications